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Antibiotic resistance is increasingly a health and financial burden on the global population. Use 
and misuse of antibiotics has led to increased frequencies of antibiotic-resistant infections 
worldwide, leading to fatalities as well as greatly increasing healthcare costs. To combat this, 
researchers have done much work to expand to the field of antibiotics, delving back into old 
compounds and testing massive libraries of compounds with rapid screening techniques. 
Tamoxifen is one such compound that is primarily used as an anticancer agent, but displays 
many useful other characteristic, including antibacterial effects. However, the mechanism of the 
antibacterial effects of tamoxifen are poorly documented. My research was aimed at both 
improving the effectivity of tamoxifen as an antibacterial and elucidating the mechanism of 





CHAPTER 1. ANTIBIOTICS 
Antibiotics have a relatively short history, with development beginning in the 1930’s, slowly as 
the idea was adopted, exploding in the 1960’s, and decelerating significantly to the present day 
as many natural sources of novel antibiotics are exhausted. A brief history of antibiotics, along 
with a survey of the majority of relevant antibiotic classes, their histories, mechanisms, and uses 
are presented in this chapter. 
1.1 The discovery and development of antibiotics 
In 1928, Alexander Fleming took a vacation from his work at St. Mary’s, leaving behind Petri 
dishes with bacterial cultures. Upon his return, he found the plates a mess of contamination. As he 
sorted through and discarded the ruined cultures, he noticed that one plate had mold growing along 
the edge. Furthermore, there was a clear zone between the mold and the nearest bacterial colony. 
Ever the scientist, Fleming pursued an explanation to this phenomenon which culminated in the 
discovery of the first known antibiotic: penicillin[1]. From such odd beginnings, an entirely new 
branch of medicine developed. It took over a decade for penicillin to make the transition to clinical 
trials, where it was used to treat a patient with a staphylococcal infection in 1941. Although that 
patient died due to a paucity of the compound[2], penicillin was moved into large scale production 
in time for World War II. Fleming and the two scientists who isolated penicillin and developed the 
production process, Howard Florey and Ernst Chain, were awarded the Nobel Prize in 1945. This 
monumental success opened the floodgates which swept into the so-called “Golden Age” of 
antibiotics, a period from the 1950s to the late ‘60s which saw the discovery and clinical 
development of many antibiotics which remain relevant to this day[3]. The euphoria of innovation 
soon wore off as the problem of antibiotic resistance cropped up within a decade of the introduction 
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of penicillin. This predicament is one of the most concerning developments in the medical field 
and some have even speculated that should this dilemma continued unchecked it will lead to a 
world where antibiotics are ineffective, a regression of a century’s worth of medical advances[4]. 
Antibiotic resistance is already responsible for tens of thousands of deaths worldwide, and 
significantly impacts the worldwide economy through increased treatment costs and hospital days, 
costing millions of man-hours[5]. Fortunately, awareness of this issue is high and research groups 
worldwide now strive to overcome resistance mechanisms and unearth or create novel antibiotics.  
1.2 Major antibiotic classes 
There are many classes of antibiotic classes which target various aspects of microbial cells. This 
section is arranged in an outward-in manner, beginning with antibiotics that affect the cell wall 
and moving to antibiotics with internal targets. 
1.2.1 Antibiotics which target or affect the bacterial cell wall 
The following antibiotic classes either directly interact with the bacterial cell wall or else act in 
some manner to inhibit or disrupt the growth of the bacterial cell wall. 
1.2.1.1 Lipopeptides 
Lipopeptides, as the name suggests, are cyclic peptides with attached lipid moieties. These 
antibiotics are used for skin and skin structure infections. They are highly effective against Gram-
positive bacteria, including MRSA[6]. Daptomycin (Fig. 1) was the first clinically available 
lipopeptide. A fermentation product of Streptomyces roseoporus, it was first developed by Eli Lilly 
and Company under the name LY146032 in 1986. The rights were acquired by Cubist 
pharmaceuticals with clinical studies beginning in 1999[7].  Lipopeptides such as daptomycin 
display a unique mechanism (Fig. 2) of action among antibiotics; the lipid ‘tail’ of the lipopeptide 
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inserts into the cell membrane of the bacteria, causing rapid depolarization and ion efflux, leading 
to an arrest of DNA, RNA, and protein syntheses, ending in cell death[6]. Resistance has not been 
described in a laboratory setting, but a patient who displayed daptomycin-resistant Staphylococcus 
aureus bacteremia has been documented and there is growing concern over reports of more cases 
of daptomycin-resistance[8]. 
 
Figure 1. Structure of daptomycin 
 




Polymyxins such as colistin (Fig. 3) are large, cyclic peptides with long hydrophobic tails derived 
from species Bacillus polymyxa which were first isolated in 1940[9]. Unfortunately, although 
polymyxins show excellent broad spectrum activity, they have several disadvantageous side 
effects, including relatively high neuro- and nephrotoxicity, limiting their clinical use to antibiotics 
of last resort, to be used only when mainline antibiotics have failed[10]. The primary use of 
polymyxins is in topological creams and ointments, for instance, generic “triple antibiotic 
ointment” contains polymyxin B. Polymyxins are surface active peptides, cationic agents which 
bind to the anionic cell membrane of bacteria, leading to a detergent effect which disrupts cell 
membranes (Fig. 4). The polymyxins have an especially high affinity for the lipid moiety of 
lipopolysaccharides, displacing magnesium and calcium ions[10]. Resistance to polymyxins is 
intrinsic in microbial strains which have alterations in lipid A which lead to lower binding. 
Acquired resistance generally takes the form of altered or displaced phosphate groups on the 
lipopolysaccharide, as well as changes in cell membrane composition[11]. 
 




Figure 4. Mechanism of polymyxin action. Adapted with permission under open-access policy from [12] 
1.2.1.3 Glycopeptides 
Glycopeptides are glycosylated, cyclic, nonribosomal peptides, such as vancomycin and 
bleomycin. Vancomycin (Fig. 5) was first used in 1958 and thanks to its activity in patients who 
were refractive to other antibiotics, it received quick approval from the FDA. In the next few years, 
however, newer β-lactams emerged which had the same coverage as vancomycin and were 
considered to be less toxic, so vancomycin faded from the public eye. Recently it has experienced 
a resurgence due in large part to the necessity brought on by antibacterial resistance[13]. 
Glycopeptides in general have narrow-spectrum coverage, primarily used to treat Gram-positive 
bacteria, and also suffer from poor bioavailability and various deleterious side effects[14]. 
Glycopeptides, like β-lactams, inhibit cell wall synthesis. This is accomplished by binding to a 
peptidoglycan, the building blocks of the bacterial wall, where the peptidoglycan ends in 
consecutive alanine residues, called the D-Ala-D-Ala moiety, which is specific to bacterial cell 
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walls. Glycopeptides bind this moiety, sterically shielding it from modification and preventing 
further cell wall synthesis, leading to cell death[15]. Resistance genes such as VanA generate 
alternate moieties from D-Ala-D-Ala which allow for cell wall synthesis but restrict glycopeptide 
binding[16]. 
 




β-lactam (Fig. 6) is an umbrella term for any antibiotic that contains a β-lactam ring. This broad 
group includes penicillins, cephalosporins, monobactams, and carbapanems, to name a few. The 
general mode of inhibition for β-lactams is disruption of bacterial cell wall biosynthesis. This 
group of antibiotics is generally more effective on Gram-positive bacteria. β-lactams are the most 
widely used antibiotic group, constituting 50% of global antibiotic usage[17]. This section will 
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also discuss β-lactamase inhibitors, compounds which are used as a co-treatment with β-lactam 
antibiotics to overcome a common mode of resistance, β-lactamases. The method by which β-
lactams inhibit cell wall synthesis is the binding of transpeptidases, which earns those proteins the 
alternative name of penicillin-binding proteins (PBPs), proteins which are bound by molecules 
containing β-lactams. The binding of these various proteins generally prevents a transpeptidation 
reaction which halts crosslinking of the peptidoglycans in the bacterial cell wall, leading to cell 
lysis. The exact mechanism is complex, and some penicillins do not inhibit transpeptidation to 
achieve cell lysis[18]. Recently, it was shown that rather than simply inhibiting transpeptidation, 
β-lactams “stimulate a deleterious futile cycle of cell wall synthesis and degradation by their target 
machineries that contributes to their lethal activity”[19]. In short, β-lactams induce a continual 
building and recycling of peptidoglycan, depleting the precursor pool but never achieving cross-
linkage. 
 




As mentioned in the introduction, penicillin was the first antibiotic ever characterized. The 
penicillin class quickly grew and is one of the most substantive subclasses of antibiotics available. 
The penicillins all share three components: the β-lactam ring, an attached thiazoldine ring, and a 
side chain. This group includes penicillin, ampicillin, and methicillin. Natural penicillins are 
generally used to treat enterococci, streptococci, and staphylococci which do not present β-
lactamases[20]. To treat bacteria which presented penicillinase, an enzyme which opens the β-
lactam, rendering the drug inert, semi-synthetic derivatives of natural penicillins are used, such as 
methicillin, which presents a large side-chain to restrict access of the enzyme to the β-lactam 
ring[21]. This extends the antibacterial coverage to most staphylococcus, however it has also lead 
to one of the most prominent instantiations of antibacterial resistance – methicillin-resistant 
Staphylococcus aureus or MRSA. By modifying the side chain with an amine group, 
aminopenicillins were developed. These penicillins were the first to show activity against Gram-
negative bacteria and include ampicillin and amoxicillin[20]. Finally, several penicillins have been 
developed which display a wide coverage, dubbed ‘extended-spectrum penicillins, including 
carbenacillin and piperacillin. These penicillins show increased activity against Pseudomonas 
sp.[22]. Penicillins are widely used in primary care and are commonly co-administered with β-
lactamase inhibitors. 
1.2.1.4.2 Cephalosporins 
Cephalosporins were first discovered by Guiseppe Brotzu in the late 1940s and were isolated in 
the early 1950s[23]. Although these compounds themselves were not particularly potent 
antibiotics, by removing the natural side chains and isolating the common core of a β-lactam ring 
condensed with a dihydrothiazine ring, referred to as 7-aminocephalosporanic acid (7-ACA), 
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development of more powerful cephalosporin generations was possible[24]. Cephalosporins show 
very broad activity and can be generally categorized by generation. The first generation, including 
Cephalexin and Cephradine, have relatively simple structures and generally have a methyl side 
chain at C3. They perform well against Gram-positive bacteria but are lacking with regards to 
Gram-negative bacteria. Second generation cephalosporins, such as Cefuroxime and Cefotiam 
introduced an α-iminomethoxy group at the C7 side chain, which increased resistance to β-
lactamases, and the attachment of an aminothiazole ring to the C3 side chain, which increased 
binding affinity and antimicrobial activity[25]. The third generation, including Cefixime and 
Cefdinir, moved the iminothiazole group to the C7 position and utilized various groups at the 7α 
position to increase β-lactamase resistance[25]. The fourth generation improved activity against 
Gram-negative bacteria by adding a positively charged element to make the molecules 
zwitterionic, allowing them to diffuse through Gram-negative bacterial membranes more easily 
than their predecessors[25]. The latest generation, the fifth, is still young and as such only contains 
a handful of compounds, including Ceftobiprole and Ceftaroline. These compounds are the only 
cephalosporins effective against MRSA, both having their C3 side chain tailored specifically to 
bind to PBPs in MRSA[26]. Although these two compounds have been shown to be effective 
against MRSA, the rise of extended-spectrum β-lactamases has largely made cephalosporins 
useless in treating resistant bacteria[27]. 
1.2.1.4.3 Cephamycins 
Cephamycins are structurally very similar to cephalosporins, but have a methoxy group at the 7α 
position. This group was discovered in 1972[28] and includes compounds such as cefoxitin and 
cefmetazole. These compounds exhibit a broad spectrum of activity and the methoxy group plays 
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a key role in increasing resistance to β-lactamases. As such, these compounds are highly effective 
against Gram-negative bacteria.  
1.2.1.4.4 Carbapenems 
Carbapenems share an almost identical core with penicillins, except that a carbon is substituted for 
the sulfur in the 5-membered ring which additionally has a degree of unsaturation. The first 
carbapenem isolated was theienamycin, isolated from Streptomyces cattelya with some difficulty, 
due to the compound’s instability[29]. Thienamycin displayed an unusually broad antibacterial 
spectrum for a β-lactam, but its aforementioned instability made it unfit for clinical usage, as it 
shows a tendency to dimerize into an inert form as the concentration increases[29]. The first 
clinically viable carbapenem was imipenem, created by derivatizing the terminal amine to a 
formamidine. This compound showed activity against both Gram-positive and Gram-negative 
bacteria, as well as retaining activity against β-lactamase producers[30]. The carbapenem family 
is of particular importance for its activity against Pseudomonas aeruginosa and Enterococcus sp 
and is also boasts the broadest spectrum of the β-lactam family of antibiotics. In recent years, 
however, more and more cases of resistance to carbapenems have surfaced, reducing the utility of 
these potent drugs[31]. 
1.2.1.4.5 Monobactams 
The monobactams, as the name suggests, are antibiotics with an unfused, lone β-lactam ring. First 
isolated in 1981, the only clinically used monobactam, aztreonam, was synthetically derived 
through a structure-activity relationship (SAR) study, where subtle iterations of a compound are 
synthesized to parse out a more effective molecule, of naturally occurring monobactams[32]. 
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Monobactams are particularly effective against Gram-negative bacteria such as Pseudomonas 
aeruginosa but do not bind well to Gram-positive PBPs, limiting their use clinically. 
1.2.1.4.6 Trinems 
Trinems, or tribactams, are a new class of β-lactams which contain a tricyclic ring. They display 
broad spectrum activity against aerobic and anaerobic Gram-positive and Gram-negative bacteria, 
and are highly resistant to β-lactamases[33]. To the author’s knowledge, no trinems are currently 
in use clinically. 
1.2.1.4.7 β-lactamase inhibitors 
β-inhibitors are compounds that, while not having much antibiotic activity on their own, impede 
or disrupt the bacterial enzymes which break β-lactam rings, thereby increasing the microbe’s 
sensitivity to a β-lactam antibiotic which is used as a co-treatment. β-lactamase inhibitors may 
have a β-lactam core, as in the case of clavulanic acid, sulbactam, and tazobactam, or they may 
not, as in the case of avibactam. These inhibitors are usually used in the treatment of Gram-
negative bacteria as the general mode of resistance for Gram-negative bacteria is the production 
of β-lactamases, whereas Gram-positive bacteria tend to exhibit resistance due to variant 
PBPs[34]. 
1.2.2 Antibiotics which target the ribosome 
There are many different classes of antibiotics which bind to the ribosome and negatively affect 






Aminoglycosides are compounds whose basic structure consists of one or more aminated sugars 
joined to a dibasic cyclitol; they display broad-spectrum antibiotic coverage[35]. The first 
aminoglycoside used clinically, streptomycin (Fig. 7), also carries the honor of being the second-
most widely used antibiotic, after penicillin. In 1943, Albert Schatz joined the laboratory of Selman 
Waksman for his PhD studies. The Waksman lab at the time had identified several candidate 
microbes which secreted compounds that were effective against tuberculosis (TB). Schatz was 
able to isolate streptomycin, and clinical trials began in 1945. The treatment proved effective, 
winning Waksman the Nobel prize for the discovery, causing some controversy as Waksman 
refused to acknowledge Schatz’ role in the work[36]. In the 1970’s, many semisynthetic 
aminoglycosides were developed such as dibekacin and amikacin, but recently the development 
of new aminoglycosides has slowed considerably[35]. Aminoglycosides bind at the A-site in the 
bacterial ribosome. Although this binding does not prevent protein synthesis, it impairs the 
proofreading process, leading to the production of aberrant proteins and eventually cell death[37]. 
In E. coli, for example geneticin and paromomycin bind adjacent to a pair of adenines, A1492 and 
A1493, which will flip out from helix 44, signaling a codon-anticodon match. When there is a 
mismatch, the pair does not flip out, signaling the cell that a mismatch has occurred. When 
aminoglycosides are bound, the adenine sensor pair remains flipped out, signaling the cell to 
continue translation, essentially muting the mismatch warning system[38]. A primary means of 
antibacterial resistance to aminoglycosides is severely reduced uptake by means of membrane 
impermeabilization, which holds high clinical relevancy since it results in moderate resistance 
across all aminoglycosides[39]. Aminoglycosides are also susceptible to modification by N-
acetyltransferases and O-nucleotidyltransferases, which make the compounds unsuitable for 
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ribosomal binding. This mode of resistance is more challenging in the long run, as many of these 
enzymes are encoded on transposable elements, making dissemination of resistance possible[37]. 
 
Figure 7. Structure of streptomycin
 
1.2.2.2 Tetracyclines 
The tetracyclines are a group of compounds with a fused 4-ring system, generally recognized as a 
naphthacene core (Fig. 8). The first clinical usage of tetracycline was in 1948 when a 5-year old 
boy with a ruptured appendix faced complications after surgery. When the few other antibiotics 
available were ineffective, the boy’s parents consented to allow the use of a previously untested 
compound, Aueromycin. The boy made a full recovery and tetreacycline compounds were 
recognized as an important new treatment[40]. Currently, tetracyclines are considered first-line 
treatments for a variety of diseases, including Rocky Mountain spotted fever and Lyme disease. 
This group of compounds shows broad-spectrum activity with little innate resistance, although 
acquired resistance has become an increasing issue in recent years. Tetracyclines act by inhibiting 
protein synthesis by binding to the 30S subunit and blocking incoming aminoacyl-tRNAs from 
binding, shutting down translation[41]. The binding pocket for the compound(Fig. 9) is thought to 
be composed of the S7 protein and several rRNA residues on the 16S subunit, although there are 
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other interactions revealed by footprinting experiments that suggest other possible binding 
modes[40]. Additionally, there are ‘atypical’ tetracyclines such as chelocarrin which disrupt cell 
membranes at higher concentrations in addition to attacking the ribosome[42], however these 
compounds display adverse side effects and are not used clinically[41]. The major mechanism of 
tetracycline resistance is efflux pumps, which reduce the intracellular concentrations of the 
compound to sub-inhibitory levels. The pumps are encoded on the mobile tet genes, and are spread 
horizontally[41]. A second mechanism of resistance is ribosomal protection proteins (RPPs), 
cytosol soluble proteins which displace tetracyclines from their binding sites in a GTP-dependent 
manner[43].  
 
Figure 8. Structure of tetracycline 
 
Figure 9. The tetracycline-binding aptamer. A) Secondary structure and C) crystal structure of the aptamer. Tetracycline shown 
in green. B) Tetracycline structure D) Base triplet between A9, A44, and A55. E) Location of A13 and A50 with respect to 




The amphenicols, which include chloramphenicol and florfenicol, are a group of relatively small 
molecules with a phenylpropanoid core. Chloramphenicol (Fig. 10) was first isolated in 1949, and 
thanks to its simple structure, was the first antibiotic to be completely synthesized chemically[45]. 
It shows broad spectrum coverage but has deleterious side effects and as such is reserved for 
treatment only in cases where other antibiotics have proven ineffective. Amphenicols target the 
50S ribosomal subunit, where they prevent chain elongation by inhibiting the peptidyl transferase 
center of the ribosome (Fig. 11). Specifically, amphenicols bind the A2451 and A2452 residues of 
the 23S rRNA and prevent peptide bond formation[46]. Enzymes such as acetyltransferases have 
been found to confer amphenicol resistance, such as in Streptococcus haemolyticus and 
faecalis[47]. Another mechanism of resistance, discovered in Haemophilus influenza, causes a 
decrease in amphenicol uptake due to a permeability barrier stemming from the loss of an outer 
membrane protein[48]. 
 




Figure 11. Interaction of chloramphenicol with the peptidyl transferase cavity. A) Chemical structure diagram of chloramphenicol showing the 
interactions (arrows) of its reactive groups with the nucleotides of the peptidyl transferase cavity. B) Secondary structure of the peptidyl transferase 
ring of D. radiodurans showing the nucleotides involved in the interaction with chloramphenicol (coloured nucleotides). C) Stereo view showing 
the nucleotides interacting with chloramphenicol at the peptidyl transferase cavity of D. radiodurans. The antibiotic is shown in green. Nucleotide 






Macrolides (Fig. 12) are large macrocyclic lactone rings with one or more pendant glycosidic 
residues, commonly cladinose and desosamine, and the ring size ranges from 14- to 16-membered. 
Most macrolides are semi-synthetic derivatives of erythromycin, a macrolide which was first 
isolated from soil bacteria in 1949[50]. Compounds such as clarithromycin, a 14-membered ring 
with cladinose and desosamine decorations, and azithromycin, a 15-membered ring with an 
inserted nitrogen, show activity against Gram-positive bacteria, with limited usage against Gram-
negative bacteria. Because macrolides naturally accumulate in the lungs, they are commonly used 
to treat respiratory infections. As all currently used macrolides are derivatives of erythromycin, 
there are limited possibilities for future development. A method starting with basic building blocks 
of macrolides has been proposed as a highly modular, fully synthetic alternative route[50]. 
Ketolides, such as telithromycin, are macrolides in which the C3 cladinose of erythromycin has 
been replaced with a ketone. In the case of telithromycin, the compound also has an alkyl-aryl arm 
that extends off a carbamate fused to the main ring structure. These compounds bind in the same 
location as the other macrolides, but show increased acid resistance thanks to the lack of the labile 
cladinose group[51]. Macrolides are translation inhibitors, binding to the 50S subunit within the 
ribosomal exit tunnel, a cavity which extends from the peptide transfer center through the 50S 
subunit, through which the nascent peptide extrudes from the ribosome into the cytosol (Fig. 13). 
The binding site is just before a natural constriction point created by ribosomal proteins L4 and 
L22 jutting into the exit tunnel. Macrolides block off this tunnel, preventing peptide extrusion, 
stalling the ribosome and thereby halting translation. Ketolides, lacking the bulky cladinose ring, 
allow for a longer peptide segment to be formed before translation is halted[52]. Beyond a simple 
steric obstruction, it has been indicated that the stalling of the ribosome occurs in a context-specific 
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manner, that is, specific sequences and amino acids result in stalling due to interactions of the 
macrolide within the tunnel causing upstream effects at the peptidyl transferase center[53]. One 
common mode of resistance to macrolides is modification to the 23S rRNA, specifically the 
alteration of A2058, which plays a key role in the binding of macrolides. Resistance genes code 
for proteins which methylate this position, leading to a loss of binding affinity and decreased 
sensitivity to the compound. Other methylations, such as at G748 also lead to resistance[54]. Drug 
efflux is another common mode of resistance. 
 
Figure 12. Structure of A) erythromycin and B) telithromycin 
 




Streptogramins are macrocyclic lactones subdivided into two classes: A and B. The two classes 
work synergistically, as they are bacteriostatic when used alone but bactericidal when used 
together, and so are used as mixtures, as with quinupristin/dalfopristin (Fig. 14). The 
streptogramins are most effective against Gram-positive bacteria and are generally used to treat 
cases of vancomycin resistant Staphylococcus and Enterococcus. Class A streptogramins have 
macrolide-like structures and generally have a high degree of unsaturation, whereas class B 
streptogramins are cyclic depsipeptides[56]. Streptogramins, like macrolides, halt translation and 
even have a similar binding site. Streptogramin A blocks substrate access to the acceptor and donor 
sites of the PTC, while streptogramin B prevents peptide bond synthesis and induces the 
detachment of incomplete protein strands and blocks the exit tunnel similarly to macrolides[56]. 
The synergy of the two classes stems from conformational changes to the 23S rRNA which occur 
upon streptogramin A binding which increase affinity for streptogramin B[57]. Resistance is 
acquired in a similar manner to macrolides: the chemical modification of the 23S rRNA leads to 
decreased binding efficiency[57]. 
 





The oxazolidinones are a relatively new (clinically approved in 2000) antibiotic which are highly 
active against Gram-positive bacteria but show limited activity against Gram-negative bacteria. 
Linezolid (Fig. 15) is the first of a small number of currently available oxazolidinones; its primary 
uses are against penicillin resistant S. pneumoniae, endocarditis, vancomycin-resistant strains, and 
tuberculosis[58]. Although this compound shows excellent bioavailability, it does present some 
unwanted side effects, such as gastrointestinal disturbance. Oxazolidinones bind to the 50S subunit 
of the ribosome. Linezolid competes with chloramphenicol and lincomycin for binding, indicating 
that they have close binding sites, but does not inhibit peptidyl transfer as the other two. 
Oxazolidinones inhibit the binding of fMet-tRNA to the P-site and inhibits the formation of the 
70S ribosomal complex. In ribosomes that have already formed the 70S, oxazolidinones prevent 
translocation of the peptidyl-tRNA from the A-site to the P-site[59]. The only resistance 
mechanism described for linezolid thus far is target modification. The most common mutation is 
a change of 23S G2576 to U2576, but other modifications conferring resistance have been found 
at position 2032 and 2447 in the 23S of E. coli[58]. 
 






 Lincosamides (Fig. 16) are small antibiotics containing a mycarose sugar which, although 
structurally distinct from macrolides, nevertheless operate in a similar fashion and share common 
binding sites and modes of resistance. The lincosamides, unlike macrolides and streptogramin B, 
directly interfere with the peptidyl transfer reaction[60]. Lincosamides are primarily used to treat 
infections from anaerobic bacteria and have broad-spectrum coverage. Clindamycin is one 
clinically available lincosamide, which is commonly used in dentistry[61] and can also be used to 
treat some cases of MRSA[62]. Clindamycin can also be used to great effect as an antimalarial 
when used in combination with chloroquine or quinine[63], but its clinical use as an antibacterial 
is marred by several side effects as well as an increased risk in Clostridium difficile colitis in 
hospital patients[64]. 
 
Figure 16. Structure of lincomycin, a lincosamide 
1.2.3 Antibiotics which have other internal targets 
Some antibiotic classes have targets within the bacterial cell which are not on the ribosome, such 




Quinolones (Fig. 17) are broad-spectrum antibiotics based on a 4-quinolone core. The first 
discovered compound was nalidixic acid in 1962, which is technically a napthyridine due to the 
extra nitrogen in its ring structure. Other derivatives were subsequently developed and put to use 
clinically, but the compounds suffered from poor bioavailability and relatively low activity[65]. 
The quinolone family received renewed interest with the development of a fluorinated derivative, 
flumequine. Although the use of this compound was discontinued due to ocular toxicity, the 
production of quinolones moved strictly toward fluorinated derivatives, creating the subclass of 
fluoroquinolones[66]. These fluorinated derivatives showed superior bioavailability and 
effectivity, with ciprofloxacin currently the most potent quinolone available on the market, used 
primarily in the treatment of Gram-negative infections[65]. Quinolones target two key type II 
topoisomerases, DNA gyrase and DNA topoisomerase IV (Topo IV). The former protein is 
responsible for introducing negative supercoils into bacterial DNA, an aspect of crucial importance 
to bacterial replication which is not present in eukaryotic cells, making it an ideal target.61 The 
latter protein is a decatenating enzyme which is responsible for unlinking sister chromosomes 
during replication and for relaxing positive supercoils in DNA[67]. Quinolones bind to the 
gyrase/topoisomerase-DNA complex, blocking DNA synthesis and halting cell division[68]. 
There are several major modes of resistance to quinolones. First, chromosomal-mediated 
resistance stemming from mutations in the gyr genes can lead to decreased binding and low-level 
resistance. Additionally, effective drug concentration can be reduced either through decreased 




Figure 17.General structure of quinolones. The R’ group is usually piperazine, the presence of fluorine makes the compound a 
fluoroquinolone
 
1.2.3.2 – Sulfa drugs 
Sulfa drugs, or sulfonamides (Fig. 18), were technically the first antibiotics, developed in the early 
1930’s by Gerhard Domagk[69]. These compounds inhibit the production of folic acid by targeting 
dihyropteroate synthase. Although the use of sulfonamides quickly spread, they were blighted by 
high incidence of allergic reactions, which could be extremely severe in some cases, and by 
widespread resistance[70]. They are still sometimes used in combination with inhibitors of 
dihydrofolate reductase, a protein further down the synthetic pathway to folic acid, such as 
trimethiprim. 
 






CHAPTER 2. ASSAYS AND TECHNIQUES 
In order to discover antibiotics, characterize their structure, and elucidate their mechanisms, a 
wide variety of assays and chemical techniques are utilized. This chapter will examine many of 
the tools which scientists use to discover, identify, and characterize antibiotics. This chapter is 
not concerned with organic synthesis or the precepts of synthesizing synthetic or semi-synthetic 
antibiotics. We will begin with how advances in screening allow for the identification of 
potential antibiotic candidates, then examine various visual and analytical techniques and how 
they have aided in the discovery and development of currently used antibiotics. 
2.1 Compound screening 
The first step in the development of a new antibiotic is the identification of a potential compound 
which displays antibacterial activity. As there are countless organisms which produce diverse 
compounds, as well as synthetic compounds developed for other purposes, it is necessary to utilize 
efficient screening methods to test a vast number of potential candidates rapidly. In the 1940s, 
Alexander Waksman developed a method to screen compounds from soil-derived Streptomyces 
samples by looking for zones of growth inhibition on an overlay plate, similar to the method by 
which Fleming accidentally discovered penicillin[71]. Waksman’s method led to the discovery of 
streptomycin, discussed earlier. The “Waksman Platform” was responsible for the discovery of 
most of the major antibiotic classes during the Golden Era. Since then, screening methods have 
evolved as the number of compounds isolated from natural sources has skyrocketed[72]. Currently, 
compound screening can be done rapidly and efficiently in an automated fashion. Advances in 
engineering and robotics have led to high-throughput instruments capable of assaying hundreds if 
not thousands of compounds a day[73]. Newer machines are even capable of ultra-high throughput, 
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processing hundreds of thousands of compounds a day[74]. Recently, an interesting technology 
for screening uncultivable microbes, which comprise the vast majority of microbial populations, 
based on genetic data, but cannot be grown under standard laboratory conditions. Taking 
advantage of advances in microfluidics, Nichols et al. was able to create an isolation chip (dubbed 
iChip) which allowed for culture separation and incubation from a given water or soil sample[75]. 
Screening assays can be based on various methods of detection, including radiochemical, 
fluorescence and luminescence.  
Radiochemical assays are highly precise, for example, in vitro receptor assays can detect binding 
constants (Kd) in the pM range, and can detect protein-protein interactions at the nM range[76]. 
Radioisotopically-labeled compound uptake can also be monitored precisely. This method suffers 
drawbacks from high reagent cost, and subsequently high assay cost, as well as difficulty in 
miniaturization[74]. Radiolabeling is discussed in greater detail in a later section. 
Figure 19. The iChip (a) consists of a central plate (b) which houses growing microorganisms, semi-permeable membranes on each 
side of the plate, which separate the plate from the environment, and two supporting side panels (c). When the central plate is 
dipped into a cell suspension in molten agar, the through-holes capture small volumes of the suspension which solidify as plugs. The 
membranes are attached and the iChip is placed in a soil sample. Adapted with permission from [76] 
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Fluorescent assays are diverse, cost-effective, and have low detection limits. There are many 
fluorescent detection methods, such as fluorescent anisotropy (FA), which uses molecular rotation 
to measure bimolecular association events[77]. A common fluorescent method is fluorescence 
energy resonance transfer, or FRET. FRET is based on energy transfer between a fluorophore 
donor and a chromophore acceptor which is distance-dependent. The fluorescent emission of the 
acceptor can be resolved in a time-dependent fashion. FRET can be used for ligand-binding, 
enzyme turnover, and even whole-cell assays[76]. 
 
Figure 20. Conditions required for FRET. Adapted from [78] 
Chemiluminescence (CL) assays are similar to fluorescence assays and the equipment used in these 
assays are often capable of measuring luminescence as well as fluorescence. CL predominately 
takes advantage of luciferase reporter genes in cell based assays and alkaline 
phosphatase/horseradish peroxidase in high-sensitivity enzyme-linked immunoabsorbent assays 
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(ELISA). In fact, CL is most commonly applied in immunoassay-based detection[74]. The use of 
a chemiluminescence in an assay is clearly laid out by examining the ELISA assay in more detail. 
In direct ELISA, an antibody to a particular antigen is linked to a reporting enzyme. This 
conjugated antibody is then added to a sample containing the antigen to the antibody. The substrate 
for the enzyme is added, allowing for a measurable change in the solution of color or light[77]. If 
luciferase is linked to the antibody, luciferin can be used as a substrate and the subsequent 
luminescence measured and quantified. There are also indirect and ‘sandwich’ methods for ELISA 
which have additional steps, for instance an indirect ELISA will use an unlabeled primary antibody 
which binds the antigen and a labeled secondary antibody which binds the primary antibody[79]. 
Indirect ELISA has several advantages: multiple secondary antibodies can bind the primary 
antibody, giving a stronger signal, and different primary antibodies can use a single secondary 
antibody. 
 
Figure 21. ELISA methods. Ag = antigen, E = enzyme 
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Recent advances in genetics have had an astounding impact on natural product discovery. As more 
and more genetic information becomes decrypted and catalogued, the field of metagenomics has 
risen to profoundly shape the way in which researchers approach natural products. As techniques 
to garner genetic information improve, the libraries of genomic information expand. Sequencing 
is often done via the Sanger method, which utilizes fluorescently labeled dideoxynucleotides to 
arrest DNA synthesis, leaving a truncated molecule. Through many rounds of synthesis, fragments 
of every conceivable length are created, which are then separated by size electrophoretically, with 
the fluorescent tag indicating which nucleotide is at the end of the sequence. In this manner, a 
Sanger ‘trace’ is created which is converted to a DNA sequence[80]. 
Although Sanger sequencing is the traditional route, newer generations of sequencing technology 
have utilized different methodologies. 454 sequencing, for example, utilizes a luciferase 
luminescence based assay to determine the base being added to the sequence in real time, however 
this technology struggles with homopolymeric sequences (multiples of the same nucleotide in 
sequence)[80]. 
 Using sequence analysis, genes which encode biosynthetic pathways can be parsed out and many 
novel compounds have been discovered in the genomes of microbes which cannot be cultivated 
using normal methods[81]. Recently, a group developed a technique to selectively retrieve 
compounds from a crude cell extract in a reaction-dependent manner, allowing them to extract 
compounds which contained specific moieties common to antibiotics, such as β-lactams. They 
coupled their probes to information obtained from genome mining and were able to isolate a 





2.2 Whole cell and blotting assays 
2.2.1 Blotting to assess compound target 
Blotting is so called because it involves the transfer of a substance from a gel to a different surface 
for probing. A blotting technique to detect specific DNA fragments was developed by Edwin 
Southern and received his name, the Southern blot. In reference to this assay, subsequent assays 
developed to assess RNA, protein, and post-translational modifications were termed Northern, 
Western, and Eastern blots respectively. Hybrids of these assays, such as Southwestern blots, are 
also utilized but will not be discussed here. These blots are of great merit in discerning the specific 
effects of a compound on a bacterial target, with these assays being able to assess a majority of 
possible targets. The Southern blot, as previously noted, detects specific DNA fragments, which 
are separated electrophoretically, using probe hybridization. DNA fragments are run through an 
agarose gel, after which they are transferred to a nitrocellulose sheet and treated with a probe. The 
probe can be made from either DNA or RNA, and is complementary to the fragment it binds to. 
The probe is tagged either with a radioactive isotope or with a fluorescent or chromophoric 
label[83]. This technique is used to identify Human Papilloma Virus infections clinically, although 
using polymerase-chain reaction (PCR) has become more common[84]. The Northern blot is used 
to measure gene expression through the presence of RNA. An RNA extract is run through an 
agarose gel, which often contains formaldehyde to limit secondary structure, after which the RNA 
is transferred to a nylon membrane and visualized with hybridization probes of either DNA or 
RNA[85]. The probes are labelled either radioactively or else function through 
chemiluminescence. The chemiluminescent probes can either be attached to the enzyme (such as 
luciferase) or a substrate for a ligand which is attached to the enzyme, for example, a biotin-
labelled probe and an avidin-labelled enzyme[86]. Northern blots are commonly used in cancer 
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research to observe the changes in expression levels that occur in tumor cells[84]. A large database 
of Northern blots, BlotBase, has been established and contains over 700 published blots[87]. The 
Western blot is used for protein, and utilizes an antibody probe for visualization. The proteins can 
be separated on a gel based on many factors, including isoelectric point, molecular weight, and 
charge. Once the gel has been run, the proteins are transferred to a membrane, usually 
nitrocellulose, and treated with a primary antibody which binds that protein[88]. Typically, the 
primary antibody is visualized with a secondary antibody which is specific to the primary antibody, 
although single-step visualization methods have been developed[89]. Primary antibodies for a vast 
array of proteins are available commercially. SDS-Page is a common type of western blot which 
uses sodium dodecyl sulfate (SDS) to denature proteins before they are run on a polyacrylamide 
gel. After visualization, a desired protein band can be cut from the gel and used in further 
experiments. The Eastern blot is the least common of the directional blots, and is used to visualize 
post-translational modifications, such as lipids and glycoconjugates, on proteins[90]. Eastern 
blotting suffers from a somewhat indistinct definition, being viewed mainly as an extension of 
Western blotting, as the initial gel electrophoresis and membrane transfer are essentially identical, 
and the definition and purpose of an Eastern blot has varied over the years[91-93]. 
 
Figure 22. Southern blot method. Other blots follow the same general procedure with minor 
variations depending on which blot is being used 
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2.2.2 Minimum inhibitory concentration (MIC) 
For any given compound, its general effectivity against a given strain can be assessed using an 
MIC assay. There are four main methods of testing the MIC: Disk diffusion, agar dilution, broth 
dilution and broth microdilution. 
Disk diffusion is a quick and inexpensive method of testing strains against antibiotics, but suffers 
from a relative lack of accuracy compared to the other methods. In this method, an agar plate is 
seeded with an inoculum of known dilution, and an antibiotic is introduced via strip or wafer. The 
zone of inhibition generated by the antibiotic is measured[94]. The zone size is susceptible to a 
number of factors, making some disk diffusion methods only semi-quantitative[95]. 
In the agar dilution method, agar plates are prepared with an incorporated antibiotic agent with a 
range of concentrations. An inoculum is seeded on the plates and the MIC is determined as the 
lowest concentration plate which exhibits no microbial growth. One of the main problems with 
this method is the interpretation of what qualifies as the first plate with no bacterial growth[95]. 
The broth dilution method is identical in both macro and micro considerations, the difference being 
the volume of liquid. In the macrodilution method, tubes contain several mL of liquid while in the 
microdilution method, 96-well plates which hold a final volume of 100 µL are used. This makes 
the microdilution method much more economical and practical[83]. In this method, a 96-well plate 
is seeded with an inoculum, after which the compound of interest is added to the top row of wells, 
which contains a double volume of inoculum. The excess liquid is transferred sequentially down 
the rows, resulting in a 2-fold dilution of the compound with each subsequent row. In this manner, 
a total of 8 concentrations can be tested on a single plate. The absorbance of the liquid at 600nm 
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is taken before and after an overnight incubation and the resultant data can be converted to an 
MIC[96].  
2.3 Cell fraction/lysate assays 
Many of the antibiotics discussed in the first section target the ribosome. Cell-free assays are 
available for both prokaryotic and eukaryotic systems which consist of a cell extract containing 
intact ribosomes. To the extract amino acids and a luciferase plasmid are added. When testing a 
compound, inhibition of translation prevents the production of luciferase, leading to a lack of 
luminescence when luciferin is added[97]. In short, dimmer wells in the plate correspond to greater 
inhibition of translation by a given compound. With this assay, the inhibitory concentration at 
which fifty percent of translation is abated, the IC50, can be determined. 
2.3.1 RNA Footprinting 
RNA footprinting is a method of identifying interactions of RNA with proteins and ligands. In 
essence, RNA footprinting is a protection assay wherein digestion or chemical modification of 
RNA is locally inhibited through ligand binding or inherent RNA structure[98]. This provides 
reliable data on interactions within the RNA, although it cannot in itself distinguish between direct 
protection and indirectly induced protection caused by conformational changes due to interactions 
at different locations. There are various probes available for footprinting experiments and can 
either be sequence or structure specific. An example of a sequence-specific probe, as well as one 
of the more versatile, is dimethyl sulfate (DMS). DMS methylates the Watson-Crick face of 
adenine and cytosine and the Hoogsteen face of guanine[99]. Structure-specific probes, such as N-
methylisatoic anhydride (NMIA) form adducts with the 2’ oxygen regardless of base identity. This 
chemistry is utilized in RNA selective 2’-hydroxyl acylation analyzed by primer extension 
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(SHAPE) assays. SHAPE takes advantage of the adducts formed to analyze RNA folding[100]. 
The RNA fragments generated during a footprinting experiment is visualized using radioactive 
labels, most often 32P, and the experiment is highly susceptible to degradation from RNases so 
care must be taken to avoid contamination during the experiment[101]. Our lab previously used 
footprinting to observe peptide interactions in the ribosomal exit tunnel, using macrolide-peptide 
conjugates[102]. A similar technique can be done with DNA to investigate sequence-specificity 
of DNA binding proteins[103]. 
 
2.3.2 Affinity Chromatography 
Affinity chromatography is a method of extracting a desired compound from a crude extract using 
an immobilized linker which will pull out the desired compound and allow the unwanted remains 
Figure 23. RNA footprinting. a) The modifications detected by this method are methylation at N1 of adenine and N3 of cytosine, 
as indicated in yellow. (b) Primer extension. The DMS modification reaction is carried out under limiting conditions so that each 
molecule has no more than an average of one detectable modification. Reverse transcription is illustrated (product in green) 
proceeding from a radiolabeled primer (blue line) until it is blocked at a position 1 nt upstream from a methylated A or C 
nucleotide. (c) PAGE analysis of reverse transcription products. Sequencing lanes at the left are used to determine the position of 
modification for each experimental band. Adapted with permission from [101] 
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to pass through the column. This technique is most commonly used to purify proteins, but can also 
be used for other compounds, such as DNA and RNA[104].  
One method of affinity chromatography is called immobilized-metal affinity chromatography, or 
IMAC. IMAC is based on the natural affinity of transition metal ions such as Zn2+ and Ni2+ for 
histidine and cysteine[105]. Columns with immobilized metal ions have been utilized for decades 
to purify recombinant proteins by adding a series of histidines, a His-tag, which allows the 
recombinant protein to remain in the column during elution[106]. By immobilizing D-Ala-D-Ala 
moieties, discussed in chapter 1, affinity chromatography has been used for the discovery and 
purification of glycopeptide antibiotics[107]. 
More recently, IMAC has been utilized to purify membrane proteins. Although membrane proteins 
constitute approximately 30% of the human proteome, very little is known about membrane 
proteins compared to soluble proteins, which is reflected by their underrepresentation on structure 
databases such as the Protein Databank (PDB). A standardized IMAC procedure for purifying 
membrane proteins is available and has been made simpler through the development and 
optimization of detergents[108]. Additionally, IMAC is also useful in purifying proteins which 
contain the zinc-finger motif, an important DNA binding motif[109]. 




2.3.3 Thermal Shift 
Once a protein has been isolated, it is possible to verify the binding of a ligand using a thermal 
shift assay. This assay, first described in 1958, operates on the principle that the binding of a low 
molecular weight ligand often increases the thermal stability of a protein, effectively raising its 
melting point[110]. Circular dichroism and differential scanning calorimetry are common, 
inexpensive methods but they suffer from low throughput and require relatively large amounts of 
protein. Newer methods have been developed, the first being the thermofluor assay[111].  
The thermofluor assay, first described in 1991, uses a dye which binds nonspecifically to a protein 
and is displaced by water as the protein unfolds, causing an increase in fluorescence [112]. This 
method is not particularly well suited for measuring protein-protein interactions and protein 
aggregation can interfere with fluorescence. Variations of this assay have been developed with 
nucleophile-specific[113] and rigidity-sensitive dyes[114], as well as utilizing intrinsic tryptophan 
fluorescence[115].  
Figure 25. Thermal shift assays. A) The principle of Tm detection with fluorescence and B) the difference in Tm associated with ligand binding. 





Radiolabeling compounds is a technique that allows for many assays, such as binding affinity and 
saturation. When synthesizing a radiolabeled compound, many factors must be taken into 
consideration, including the half-life of the isotope – which may make experiments time-sensitive 
– and the type of radiation emitted by a given isotope, which may limit the detection methods 
available. 
A saturation analysis using a radioligand can yield the receptor affinity and can be done through 
two methods. First, the amount of radioligand added can be increased while maintaining a constant 
specific activity. Second, a constant concentration of radioligand can be used and the specific 
activity decreased by the addition of unlabeled ligand[116]. A Scatchard plot can be used to find 
the binding constant of the radioligand, Kd.  
Once Kd for a radioligand is found for a target receptor, it can be used in competition binding 
assays to determine the binding affinities of other, unlabeled compounds. A wide range is usually 
tested, against a fixed concentration of the labeled ligand[116]. Radiolabeling was utilized to 
determine that lipopeptides are membrane active[117]. 
Radiolabeling is hampered by the high costs of isotopes, the intrinsic chemical hazard of working 
with radioactive materials, and the stringent waste disposal requirements. 
2.4 Imaging 
Cell imaging is a powerful resource for visualizing cellular structures, tracking proteins, and more. 
Although the inventor of the microscope is difficult to identify exactly, light microscopy garnered 
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attention in the scientific community thanks to the insights into microscopic life it provided. Robert 
Hooke’s Micrographia and the work of Antonie van Leeuwenhoek, who used his 300x 
magnification microscope to discover red blood cells and spermatozoa - and later microorganisms 
- were instrumental in establishing the utility of the light microscope for biological studies[118, 
119]. Since these early years of development in the late 1600s, microscopy has evolved beyond 
simple optics. The advance from light microscopy to electron microscopy and x-ray techniques 
led from being able to see individual cells to being able to see individual atoms, bringing in a host 
of marvelous discoveries, including important information on antibiotic structure and function. 
2.4.1 Light microscopy 
Optical microscopy has been fundamental in both the biological and medical fields for centuries. 
There are four main modes of a typical light microscope: Bright field, where contrast comes from 
light absorbance, cross-polarized illumination, where contrast comes from the rotation of polarized 
light through the sample, dark field, where contrast comes from light scattering by the sample, and 
phase contrast, where contrast comes from the interference of different path lengths through the 
sample. Optical microscopy is ultimately limited by the wavelengths available in visible light and 
diffractions, resulting in a max resolution of 200nm, although developments in lenses and 
techniques have allowed the resolution limit to be surpassed[120]. 
Fluorescence microscopy is an offshoot of optical microscopy, utilizing lasers to excite fluorescent 
dyes and tags. A particularly important discovery in this field was the isolation of green fluorescent 
protein (GFP). Discovered and isolated from Aequorea jellyfish, GFP revolutionized fluorescent 
microscopy by making it possible to use GFP recombinately to tag proteins and structures of 
interest, allowing them to be visualized[121, 122].  
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Confocal microscopy is a powerful type of fluorescence spectroscopy. In confocal microscopy, 
illumination is confined to a diffraction-limited spot in the sample and detection is confined via an 
aperture in front of the detector, which results in an optical sectioning effect[123]. This technique 
not only provides excellent resolution but also allows for pseudo 3-dimensional images to be 
constructed by imaging sample sections from top to bottom. Advances in fluorescence microscopy 
have also enabled multiphoton microscopy (MPM). MPM uses nonlinear processes, most 
commonly two-photon excitation (2PE), although techniques such as three-photon excitation and 
second harmonic generation (SHG) are also utilized[124]. One major advantage of 2PE is tissue 
penetration, as the use of multiple low-energy photons scatter less and a signal is generated only 
at the focal point. Harmonic generation occurs when multiple photons interact with non-
symmetrical structures without being absorbed, the information divulged by this scattering has 
been used to image membranes and plant structures[125].  
 
Figure 26. Schematic of a confocal microscope 
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2.4.2 Electron microscopy 
Electron microscopy overcomes the limitations of light microscopy by using electrons as a source 
of illumination. The significantly shorter wavelength of electrons allows for resolutions up to and 
even beyond 50 picometers[126]. The two main modes of electron microscopy are transmission 
electron microscopy (TEM) and scanning electron microscopy (SEM). 
TEM is an electron approximation of standard optical microscopy: an electron beam is fired at a 
sample, the occlusion and absorption of electrons by the sample generates a bright field 
image[127]. Samples must be thin enough to allow the passage of electrons, typically 60-100 nm 
thick, and additionally biological samples must be stained with heavy metals to provide 
contrast[128]. TEM has been used to visualize the effect of tamoxifen, an anticancer drug, on 
bacterial cell walls[129]. SEM relies on energy emissions and backscattering of electrons to form 
a map of a sample’s surface. Although the technique does not offer the same resolution as TEM, 
SEM is capable of handling much larger samples and has excellent depth-of-field, making it useful 
for visualizing the three-dimensional shape of the sample[130]. Samples are generally sputter 
coated with a thin layer of gold, palladium, or other heavy metals to create a conductive layer 
which allows for imaging, although uncoated samples can be imaged[131]. 
Scanning tunneling microscopy (STM) is a method used to image surfaces at the atomic level. 
This technique utilizes a metal tip which ends in a single atom to probe the surfaces of materials 
using the principles of quantum tunneling[132]. Atomic force microscopy is a variant of the 
scanning tunneling microscope, using a cantilever with a tip ending in a single atom which passes 
over the surface of a material. As the cantilever interacts with the surface, it is displaced, this 
movement is measured to yield information about the material surface[133]. This technique has 
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allowed for chemical structure determination and even the study of single molecule recognition 
events[134]. 
2.4.3 X-ray crystallography 
One of the most powerful tools available to the biochemist is X-ray crystallography. By observing 
diffraction patterns from a crystal of a given substance, an electron density map can be derived. 
From this electron density map, the positions of atoms, their chemical bonds, and other information 
can be determined.  
The first structure of an organic compound, hexamethylentetramine, was solved in 1923[135]. This 
was followed by structures of fatty acids, which led to more complex structures, such as 
phthalocyanine in the 1930s[136]. Dorothy Hodgkin won the Nobel prize in chemistry in 1964 for 
solving the structures of cholesterol, penicillin, and vitamin B12, and she later solved the structure 
of insulin[137].  
The first protein to be solved was sperm whale myoglobin in the 1950s by John Kendrew, for 
which he won the 1962 Nobel Prize[138]. Since that success, over eighty-thousand protein crystal 
structures have been solved and can be accessed on the PDB. One of the more recent breakthroughs 
in crystallography is the solving of the whole bacterial ribosome, for which Venkatraman 
Ramakrishnan, Thomas Steitz and Ada Yonath won the 2009 Nobel Prize.  
Crystallography not only yields data on protein structure, but can visualize interactions between 
cofactors, ligands, and drugs if those compounds can be co-crystallized with the protein. One of 
the major limitations of crystallography is that crystallization conditions cannot be determined 
beforehand, and standard protocol is to optimize various solution variables in a combinatorial 
approach[139]. The crystallization is generally done in solution and must be done gradually, so as 
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to form diffraction-ready crystals and not amorphous aggregates. The precipitation conditions are 
more of a guessing game than anything, and random screening conditions seem to be more efficient 
than searches based on specific models[140]. Obtaining near-perfect crystals is of utmost 
importance especially in complex structures, as defects in the crystal structure lower the resolution 
at which the structure can be solved. As chemical bonds are no more than a few angstroms long, 
resolution below three angstroms is ideal[141]. Recently, efforts have been made to automate this 
labor-intensive process, with the goals of increasing both throughput and crystal quality[139]. 
  
 
Figure 27. Creation of a computer-generated protein from 
a protein crystal. Adapted with permission from [140] 
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CHAPTER 3. TAMOXIFEN  
Tamoxifen, specifically the Z-isomer (Fig 28), is a triphenylethylene compound and a non-
steroidal antiestrogen which is used clinically for the treatment of estrogen receptor (ER) 
positive breast cancer, as well as for adjuvant therapies. Indeed, tamoxifen is the most widely 
used anticancer drug on the market today[142]. Although this is its primary use, tamoxifen was 
not developed with cancer treatment in mind, and indeed displays several other interesting 
properties, including antimicrobial effects. This chapter will cover a history of tamoxifen, an 
overview of both its primary and alternative functions, focusing on the antimicrobial properties, 
and contains the research I undertook to expand its antibacterial properties and understand its 
mechanism of function. 
 
Figure 28. (Z)-tamoxifen 
3.1 Tamoxifen: discovery, development and usage 
3.1.1 History of tamoxifen 
Tamoxifen was discovered and developed by Imperial Chemical Industries (ICI) in 1962 and 
was initially pursued as an antifertility drug, due to its effectivity as a post-coital contraceptive in 
mice[143].  Unfortunately, the compound showed the opposite effect in human trials, actually 
inducing ovulation. As research in the 1960’s emerged linking estrogen to breast cancer, it was 
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suggested that tamoxifen, as an antiestrogen, might see some success as an anticancer agent. 
Arthur L. Walpole, the head of the fertility control program at ICI made efforts to push 
tamoxifen into medical use, supporting clinical tests in a Manchester institute. In 1973, 
tamoxifen was approved for use as a breast cancer treatment in the UK under the name 
Nolvadex[144]. Although it saw some success as an anticancer treatment, tamoxifen’s true 
triumph was as an adjuvant therapy and a chemo-preventative[145]. Initial studies were 
relatively short term, only a few years, but extended or indefinite adjuvant therapy using 
tamoxifen showed the drug to be tumorstatic and prolonged dosing prevented metastasis[146]. 
There were worries about potential side-effects from long term treatment, such as bone loss and 
risk of heart disease, but tamoxifen in fact shows bone preservation and cholesterol decreases in 
postmenopausal women[142]. Tamoxifen opened the field of selective estrogen receptor 
modulators (SERMs), and led the way for the development of other SERMs such as 
raloxifene[147]. Tamoxifen, in addition to its anticancer properties, shows promise in a number 
of other areas, only a few of which will be mentioned, namely the antimicrobial variety. 
Tamoxifen, incidentally, is a protein kinase C inhibitor, which is implicated in several off-target 
biological effects of the drug[148]. 
3.1.2 Tamoxifen as an antifungal 
Tamoxifen shows antifungal activity, with good MIC against pathogenic yeasts such as 
Candidas species as well as Cryptococcus neoformans. It was also shown to reduce kidney 
fungal burden in a murine animal model[149]. Tamoxifen functions by interfering with 
calmodulin, leading to increased calcium within the cells and affecting polarized growth. In 
Cryptococcus, this interference prevents the activation of a serine-threonine phosphatase called 
calcineurin, which is a virulence factor[150]. This is a promising treatment as compounds which 
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directly target calcineurin also act as immunosuppresants in humans, targeting calcineurin in T-
cells. Tamoxifen and other triphenylethylenes are being pursued as potential treatments which 
attack pathogenic yeasts with few side effects.  
3.1.3 Tamoxifen as an antileishmanial agent 
Tamoxifen has antiparasitic properties, showing efficacy at low doses against Leishman 
braziliensis and Leishman chagasi[151]. The studies were done in rodent models and tamoxifen 
treatment was as effective as the control drug, reducing parasite load by over 95%. Additionally, 
the subjects suffered no ill effects and had a 100% survival rate whilst every negative control 
died by 18 weeks. Current leishmanial treatments are primarily antimony based, toxic, require 
daily injections, and are losing effectivity due to the rising occurrence of resistance. Miltefosine 
is a possible alternative, showing good effectivity and boasts oral availability[152]. Tamoxifen 
shows promise as a safer, more effective treatment. The drug was found to basify the vacuoles of 
the parasite, and the mechanism was suggested to be inhibition of proton-dependent ATPase, 
although more research is required to verify the verisimilitude of this mechanism[153]. 
3.1.4 Tamoxifen as an antibiotic 
Finally, tamoxifen has antibacterial properties. The compound shows favorable MICs towards 
gram-positive bacteria such as Staphylococcus aureus, however, the mechanism is poorly 
understood at best. It was demonstrated that tamoxifen disrupts the membranes of a model 
microbe, Bacillus stearothermophilus (Fig 29), causing ultrastructural alterations leading to ion 
leakage[126]. This study reached the conclusion that tamoxifen was a membrane-active drug and 
that membrane damage was the primary mechanism of action for tamoxifen. While the data 
certainly suggests membrane effects, the exploration of the mechanism was cursory at best, 
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content to confirm membrane activity and leave it at that. In reality, the mechanism of the 
antibacterial activity of tamoxifen may be more complex. While it is certainly feasible for a non-
specific interaction to occur, it is also possible that a more targeted interaction is occurring. Very 
little research has been carried out with the goal to examine and enhance the antimicrobial 
properties of tamoxifen.  
 
One of the few studies which did examine tamoxifen by proxy assessed the antibacterial 
properties of ferrocenyl analogs of tamoxifen derivatives, bearing a second alkyl amino 
chain[154]. It was concluded that there was no general correlation between the antitumoral and 
antibacterial properties of a given tamoxifen derivative. The addition of the second alkyl amino 
chain does not appear to enhance antibacterial activity much beyond standard tamoxifen, 
however the replacement of one of the phenyls with a ferrocene group increased the MIC by a 
factor of 4 for Staphylococcus aureus (Fig 30). This study likewise looked at TEM images of 
cells before and after treatment, noting membrane damage associated with treatment with the 
tamoxifen derivatives. This study also noted significant ion efflux upon treatment, up to 95% of 
intracellular potassium in Listeria sp.  
A) B)  
Figure 29. A) untreated B. stearothermophilus. MC indicates intact membrane profile and PC indicates intact cell 
wall  B) B. stearothermophilus treated with 10 µM tamoxifen for 140 min. arrow indicates cell wall leakage. 




A more recent study of tamoxifen as an antibacterial found that it showed effectiveness against 
Mycobacterium tuberculosis, showing equivalent effectivity against multi-drug resistant and 
extreme resistant strains and the standard strain[155]. The concentrations at which tamoxifen 
Figure 30. Citrate salts of tamoxifen analogues and their MICs against various bacterial strains. Adapted  
with permission from [155] 
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was effective was well below the 50% cytotoxicity level for murine macrophages, indicating it 
may be an effective treatment with minimal off-target toxicity. This study did not explore the 
mechanism of tamoxifen’s antibacterial activity, but the researchers intend to proceed with 
testing of tamoxifen derivatives against tuberculosis. As can be seen from the ubiquity of 
tamoxifen, the compounds is a prime target for an SAR on the antibiotic effects of tamoxifen. 
The compound has well defined areas – the triphenyl portion, stereospecificity, and a terminal 
amine chain – making it straightforward to approach from a design standpoint. The literature is 
lacking in strong evidence on the effects of altering the tamoxifen structure with regards to its 
antibacterial activity, and such a study will help elucidate the mechanism, to determine whether 
it is mere membrane effect or in actuality a targeted effect. Therefore, a study examining minor 






CHAPTER 4. STRUCTURE-ACTIVITY RELATIONSHIP OF 
TAMOXIFEN 
4.1 Purpose of study 
In order to clarify the mechanism of tamoxifen as well as to enhance its antimicrobial properties, 
an SAR study of tamoxifen was undertaken. This SAR study was complemented and guided by 
MIC testing of compounds to evaluate their antibacterial activity against Staphylococcus aureus 
(SA) as well as a methicillin-resistant strain (MRSA). This study was approached through the 
hypothesis that Tamoxifen, a non-steroidal antiestrogen, displays antibacterial properties through 
an unclear mechanism. It was believed that the antiestrogenic properties of tamoxifen could be 
decoupled from the antibacterial properties of tamoxifen, converting an anticancer agent with 
Estrogen receptor (ER) specificity into a general antibiotic and that the process of structural 
modifications taken to achieve it would help elucidate the unclear mechanism by which tamoxifen 
displays antibacterial properties. Although the SAR did not get to the point of decoupling ER-
specificity, a good number of derivatives were designed, synthesized, and tested, informing of 
possible mechanistic leanings.  
4.2 Significance 
This research is of high significance because the looming threat of antibacterial resistance makes 
the pursuit of novel compounds imperative. Constant reports of new multi-resistant bacteria and a 
drying stream of new antibiotics along with the immense economic burden of infection by resistant 
microbes emphasize the urgent need for research into new antibacterial compounds. Tamoxifen 
displays antibacterial activity through an unclear mechanism and may possibly represent a new 
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class/subclass of antibiotics, making the evaluation, optimization, and mechanistic elucidation of 
this compound tremendously worthwhile.  
4.3 Synthesis of tamoxifen derivatives 
NMR and mass spectrometry data for each compound is located in appendix II. Compound 
structures and MIC data is compiled in Table 1, in the results section. 
4.3.1 Preparation of N-desmethyl tamoxifen 
Tamoxifen (Cayman Chemical) and 1-chloroethylchloroformate (Sigma-Aldrich, St. Louis, MO) 
were refluxed in dichloromethane (DCM) at 80o C overnight. The reaction mixture was 
concentrated in vacuo and resuspended in hexanes to precipitate unreacted tamoxifen, which was 
then filtered off. The chloroformate product was concentrated, then refluxed in methanol (MeOH) 
for 3 hr at 90o. N-desmethyl tamoxifen was recovered in 91% yield. 
4.3.2 Preparation of extended-alkyl derivatives 
N-desmethyl tamoxifen and a terminal bromoalkane were refluxed at 80o C overnight in DCM in 
the presence of Hunig’s base (N,N-diisopropylethylamine) in a pressure tube. The reaction was 
purified by preparative TLC. Bromopropane and bromohexane were utilized together with 
underivatized tamoxifen and desmethyl tamoxifen, created an alkyl chain series of C0 (desmethyl 
tamoxifen), C1 (tamoxifen), C3 (propyl derivative), and C6 (hexyl derivative). Yield of the propyl 
derivative was 76%, yield of the hexyl derivative was 81%.  
4.3.3 N-acetyl tamoxifen 
N-desmethyl tamoxifen was mixed with acetic anhydride in DCM for 24 hr at room temperature. 
TLC showed complete consumption of the starting material and drying under high vacuum was 
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sufficient to remove excess acetic anhydride and acetic acid. NMR of this compound showed a 
unique isomerization, thought to be across the N-C-O bonds, which resulted in near symmetrical 
peak splitting. Upon heating, the peaks reintegrated to match what was expected, as heating drove 
the racemic mixture towards a single isomer. This peak splitting was present in every subsequent 
derivative which contained the N-C-O bond, namely all the amino acid derivatives.  
4.3.4 Glycine derivative 
N-Boc protected glycine was mixed with N,N-dicyclohexylcarbodiimide (DCC) in DCM for 30 
min at 0 oC. This yielded an amino anhydride and precipitated reacted DCC as dicyclohexylurea 
(DHU). This mixture was filtered and N-desmethyl tamoxifen was added. The reaction mixture 
was refluxed overnight in a pressure tube. The Boc-product was purified using preparative TLC 
and deprotected in 10% TFA/DCM for 3 hr at room temperature then dryed in vacuo, affording 
the final product 49% yield.  
4.3.5 Alanine derivative 
N-Boc protected alanine was mixed with N,N-dicyclohexylcarbodiimide (DCC) in DCM for 30 
min at 0 oC. This yielded an amino anhydride and precipitated reacted DCC as dicyclohexylurea 
(DHU). This mixture was filtered and N-desmethyl tamoxifen was added. The reaction mixture 
was refluxed overnight in a pressure tube. The Boc-product was purified using preparative TLC 
and deprotected in 10% TFA/DCM for 3 hr at room temperature then dryed in vacuo, affording 
the final product 35% yield.  
4.3.6 Phenylalanine derivative 
N-Boc protected phenylalanine was mixed with N,N-dicyclohexylcarbodiimide (DCC) in DCM 
for 30 min at 0 oC. This yielded an amino anhydride and precipitated reacted DCC as 
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dicyclohexylurea (DHU). This mixture was filtered and N-desmethyl tamoxifen was added. The 
reaction mixture was refluxed overnight in a pressure tube. The Boc-product was purified using 
preparative TLC and deprotected in 10% TFA/DCM for 3 hr at room temperature then dryed in 
vacuo, affording the final product 42% yield.  
4.3.7 Lysine derivative 
Initial coupling was achieved as described above using Fmoc-Lys(Boc)-OH. Boc deprotection was 
achieved as described above. After concentration in vacuo, the Fmoc-protected product was 
reacted with neat piperidine for 2 hr at room temperature, the reaction was monitored via TLC. 
Excess piperidine was removed in vacuo and the reaction mixture was purified via preparative 
TLC. The purified compound was obtained in 11% yield.  
4.3.8 Guanidine derivative 
di-Boc-guanidyl triflate was mixed with N-desmethyl tamoxifen in the presence of TEA in DCM. 
The reaction mixture was refluxed overnight. The Boc-product was purified via preparative TLC 
and deprotected in 10% TFA/DCM for 3 hr. The product was recovered at a yield of 19%.  
4.3.9 Didesmethyl tamoxifen and 4-hydroxy tamoxifen 
N,N-didesmethyl tamoxifen was purchased from Toronto Research Chemicals. 4-hydroxy 
tamoxifen, the major metabolite in humans, was purchased from EMMX. Solutions were prepared 
from the compounds as purchased. 
4.4 Compound assessment 
Compounds were assessed using MIC assays as described in Chapter 2. MIC50 assays were 
performed by λ600 absorbance in 96-well plates according to CLSI protocol. S. aureus ATCC 
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29213 and Methicillin-resistant S. aureus ATCC 33591 were cultured in tryptic soy broth (TSB) 
(17g tryptone, 3g soytone, 2.5g dextrose, 5.0g NaCl, 2.5g K2HPO4 in 1L DI water) at 37 
oC. Each 
sample was tested in triplicate with both drug and vehicle controls. MIC values were determined 
using Graphpad Prism 6 software. 
4.5 Results 
MIC traces are located in appendix C. 
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Although the SAR was attenuated before the triphenyl portion could be altered, there are important 
gleanings within the results presented. The extension of the alkyl chain highlights the importance 
of the positive charge on the terminal amine and begins to expose the detriment of added 
hydrophobicity. A clear correlation between alkyl chain length and activity is seen, where 
Table 1 continued 
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didesmethyl tamoxifen is the most active compound, followed by desmethyl tamoxifen and 
tamoxifen. Extending the alkyl chain even to three units hampers activity in SA and abolishes 
activity in MRSA. Extending the chain to six units completely obliterates the activity even in SA. 
This data suggests that there is a fine balance between the degree of hydrophobicity of the alkyl 
groups attached to the tamoxifen amino group and its antibacterial activity. Additionally, the 
positive charge which the amine adopts in vivo has a tremendous effect on activity. This is further 
corroborated by the acetyl and glycine derivatives. The acetyl group effectively mutes the positive 
charge and is completely inactive. The glycine derivative, which essentially restores the positive 
charge and terminal amine, has restored activity equivalent to underivatized tamoxifen. As bulk is 
added to the alpha-carbon, it seems to have a minimal effect on activity. In almost every case, the 
compounds are less effective in MRSA. The two exceptions to this are the phenylalanine 
derivative, which is not significantly different in the SA as in the MRSA, and the lysine derivative, 
which alone shows almost a 5-fold decrease in MIC in the MRSA. Interestingly, the guanidine 
derivative is the most effective. Guanidine may have increased activity due to its relative basicity 
compared to the standard tamoxifen tertiary amine. Although no precise mechanism can be 
suggested from the findings, some insights are clearly suggested. The hydrophilicity of the amine 
end plays a key role in the mechanism, as attenuation and muting of the charge abolishes activity. 
A relatively undecorated derivative is most desirable, as in every case increasing the bulk on the 
amine end decreased activity, even in the case of lysine which offered an extra positive charge. 
While these findings do not conclusively point to a targeted interaction, they by no means rule it 
out and can even be considered possible evidence of a targeted interaction through the positive 
charge of the amine. Given the previous research which suggests membrane activity however, it is 
feasible that tamoxifen functions in a manner similar to polymyxins, which have hydrophobic tail 
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and cationic peptide section, acting as detergents and leading to ion efflux. It is also reasonable to 
suggest the mechanism may be closer to that of lipopeptides, with the hydrophobic portion 
inserting into the membrane, resulting in porosity of the membrane, resulting in ion efflux. 
However, the inactivity of 4-hyrdoxy tamoxifen may indicate the interruption of a specific, 
targeted reaction, which is in line with such a modest alteration causing such dramatic effects. In 
either case, minimal alterations to the tamoxifen amine are desirable, as evidenced particularly by 
the lysine derivative losing activity. There is much work to be done, first and foremost to attempt 
decoupling tamoxifen’s estrogen-receptor affinity from its antibacterial activity. With this initial 
groundwork in place, it is my hope that this project can be continued as new antibiotics are 
desperately needed and tamoxifen may be a doorway to novel compounds, as it has been in so 




APPENDIX  A. COLLABORATION WITH DR. DEV ARYA 
In collaboration with Dr. Dev Arya of Clemson University, aminoglycosides were linked to 
anthraquinone to limit natural defenses in the form of aminoglycoside modifying enzymes (AMEs) 
from altering the ribosome binding aminoglycoside portion. All compounds were synthesized by 
the Arya lab, and were put through a variety of tests, including a cell-free ribosomal inhibition 
assay. 
A.1 Methods 
The cell-free ribosomal inhibition assay is performed by treating E. coli cell extracts with 
compounds for testing followed by incubation with cDNA, leading to translation of a reporter 
protein, in this case luciferase.  E. Coli S30 extract kits were obtained from Promega. S30 
extract, S30 premix, amino acids, and pBESTluc circular DNA were thawed on ice. A Master 
Mix (MM) was created by combining 180 µL S30 premix, 135 µL S30 extract, 95 µL nanopure 
water, and 40 µL amino acid mix for a total volume of 450 µL. One tube of MM was sufficient 
for each compound run at 10 concentration points with 3 vehicle controls. Compounds were 
serially diluted in DMSO so that the final concentrations ranged from 1.25 µM to 2.4nM. The 
pBESTluc cDNA provided in the kit was diluted from 10 µL to 54.4 µL with sterile 1x TE 
buffer. 12.5 µL of MM were aliquoted to a 1.5 mL centrifuge tubes, followed by 0.5 µL 
compound. The tubes were then mixed and centrifuged briefly. The tubes were held at room 
temperature for 20 min, after which 0.4 µL pBESTluc solution was added. After gentle mixing 
and centrifugation, the tubes were incubated at 37o C for 60 min. The tubes were put on ice for a 
5-minute inactivation period. After gentle mixing by pipette, 5 µL were aliquoted to a white half-
volume 96-well plate (Greiner). 35 µL 1mM luciferin solution (Promega) was added to each 
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well, and the plate was read for luminescence after a 30s-shaking period. Luminescence was 
normalized to DMSO controls. Data was processed with Graphpad Prism 6.  
To verify that the compounds only showed activity in a prokaryotic ribosome, a similar 
experiment was carried out in a rabbit reticulocyte system. Rabbit Reticulocyte lysate kits were 
obtained from Promega. Cell lysate, RNasin, amino acids, and RNA were thawed on ice. Master 
Mix (MM) was created by combining 300 µL cell lysate, 5 µL RNasin, 137 µL nanopure water, 
and 8 µL amino acid mix for a total volume of 450 µL. One tube of MM was sufficient for each 
compound run at 10 concentration points with 3 vehicle controls. Compounds were serially 
diluted in DMSO so that the final concentrations ranged from 4.2 µM to 5nM. 12.5 µL of MM 
were aliquoted to a 1.5 mL centrifuge tubes, followed by 0.5 µL compound. The tubes were then 
mixed and centrifuged briefly. The tubes were held at room temperature for 20 min. after which 
0.4 µL RNA was added. After brief mixing and centrifugation, the tubes were incubated at 30o C 
for 90 min. The tubes were put on ice for a 5-minute inactivation period. After gentle mixing by 
pipette, 5 µL were aliquoted to a white half-volume 96-well plate (supplied by Greiner). 35 µL 
1mM luciferin solution (Promega) was added to each well, and the plate was read for 
luminescence after a 30s shaking period. Luminescence was normalized to DMSO controls. Data 
was processed with Graphpad Prism 6. 
Most compounds showed excellent activity against the prokaryotic ribosome, with IC50 values 
reaching low nanomolar values. The most active compounds were verified to have no activity in 






Table A1. Cell-free IC50 Data 
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APPENDIX B. NMR AND MASS SPECTROSCOPY DATA 
B.1 NMR 
 





































B.2     Mass Spectrometry 
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Figure B12 Mass spec of NL-I-45 
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Figure B13 Mass spec of NL-I-69 
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Figure B17 Mass spec of NL-I-97 
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APPENDIX C. MIC TRACES 
 
Figure C1 Tamoxifen effect on SA29213 growth 
Figure C2 Tamoxifen effect on MRSA33591 growth 
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Figure C3 desmethyl tamoxifen effect on SA29213 growth 




Figure C5 Didesmethyl tamoxifen effect on SA29213 growth 




Figure C7 NL-I-43 effect on SA29213 growth 




Figure C9 NL-I-44 effect on SA29213 growth 




Figure C11 NL-I-45 effect on SA29213 growth 
Figure C12 NL-I-45 effect on MRSA33591 growth 
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Figure C13 NL-I-69 effect on SA29213 growth 




Figure C15 NL-I-70 effect on SA29213 growth 




Figure C17 NL-I-71 effect on SA29213 growth 




Figure C19 NL-I-72 effect on SA29213 growth 




Figure C21 NL-I-97 effect on SA29213 growth 




Figure C23 4-hydroxy tamoxifen effect on SA29213 growth 
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